STATEMENT OF NEED
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Module 1 of this continuing pharmacy education (CPE)–approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.
Managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, pharmacists, and other health care professionals involved in the case management of patients with newly diagnosed multiple myeloma (NDMM).
- Assess guideline-recommended treatment combination and sequencing strategies for NDMM
- Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM
Joseph A. Kalis, PharmD, BCOP (Co-Chair)
Ambulatory Oncology Clinical Pharmacy Specialist
University of Colorado Health
Eric Cannon, PharmD, FAMCP (Co-Chair)
Chief Pharmacy Benefits Officer
General Manager, Scripius
There is no fee to participate in or claim CPE credit for this activity.
CONTINUING PHARMACY EDUCATION
St. John Fisher University Wegmans School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN #0584-9999-23-010-H01-P is eligible for 1.25 ACPE CE hours upon competion of both modules.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.
Eric Cannon, PharmD, FAMCP, has no relevant financial relationships to disclose.
Joseph A. Kalis, PharmD, BCOP, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
Technology Requirements For Virtual CPE Activities
For virtual (asynchronous, archived live, home study; synchronous webinars) CPE activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) require CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Sanofi. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Aggregate participant data will be shared with commercial supporters of this activity.